Sector News

GE to sell its biopharma business to Danaher for $21.4B

February 26, 2019
Life sciences

General Electric has moved to sell its growing biopharma manufacturing business to Danaher in a $21.4 billion deal, as the conglomerate looks to slim down its operations and pay off its lingering debt.

The trade represents an early milestone in GE’s strategy to refocus its various businesses under its newly installed chairman and CEO, Larry Culp, who took the reins last September—and who once served as Danaher’s CEO himself, from 2001 to 2014.

Danaher plans to carve out GE’s biopharma activities and operate them as a standalone business. This includes instruments and services used in biologics R&D and manufacturing, as well as the development of cell and gene therapies, such as modular therapy production lines, chromatography hardware, cell culture media and software programs.

The unit is expected to bring in about $3.2 billion in 2019 sales, with about three-quarters considered recurring revenue partly linked to its consumable products and single-use technologies. The two companies aim to close the deal in the fourth quarter of this year, with Danaher hoping to see about $100 million in cost synergies over the three years to follow.

The acquisition would also provide an “excellent complement” to Danaher’s current biologics manufacturing work, with an opportunity to provide end-to-end bioprocessing solutions to GE Biopharma’s customers, President and CEO Thomas Joyce said in a statement.

“We expect GE Biopharma to advance our growth and innovation strategy in an important and highly attractive life science market,” Joyce said, with the new purchase slotting in next to the company’s Pall, Beckman Coulter, Leica Microsystems and Sciex businesses.

GE, meanwhile, will hold on to the rest of its $17 billion healthcare business—for the time being.

“We are retaining full flexibility for growth and strategic optionality with one of the world’s leading healthcare companies, and we are pleased that our BioPharma colleagues will join a strong, established team at Danaher,” Culp said in a statement. “A more focused portfolio is the right structure for GE, and we have many options for maximizing shareholder value along the way.”

Pharmaceutical diagnostics, for example—including radiology contrast media and molecular imaging consumables—will stay within the company, linked to GE Healthcare’s stanchion medical imaging business.

GE had once planned to spin off its healthcare unit as a whole, into a 52,000-employee company with a potential enterprise value topping $70 billion. Last December it was reported that GE had filed a confidential IPO set for early 2019—but that’s now unlikely to happen following the new deal with Danaher, Culp told CNBC.

GE’s shares rose about 10% in premarket trading on the news to over $11, while Danaher’s grew at least 7.5% to over $121.

By Conor Hale

Source: Fierce Biotech

comments closed

Related News

January 22, 2023

Sun Pharma to buy Concert Pharmaceuticals for $576m

Life sciences

Sun Pharmaceutical Industries has signed a definitive agreement to buy all outstanding shares of Concert Pharmaceuticals in a deal valued at $576m. Under the deal, the company will buy all shares of Concert common stock through a tender offer for $8.00 per share in cash upfront payment.

January 22, 2023

Novo Nordisk diabetes pill wins FDA approval for first-line use

Life sciences

The Food and Drug Administration on Thursday approved Novo Nordisk’s diabetes pill Rybelsus as an initial treatment to lower blood sugar levels, a label expansion that will allow it to compete more directly with other oral drugs from Merck & Co. and Eli Lilly.

January 22, 2023

Bayer feeling more heat from activist investors, this time from Bluebell

Life sciences

Since making an ill-advised $63 billion buy of Monsanto in 2018, Bayer has faced heaps of pressure from investors that have called for the company to oust its leadership and to restructure. Now comes new pressure from a familiar source. Bluebell Capital Partners has bought an undisclosed stake in the company and is agitating for a breakup, sources told Reuters.

How can we help you?

We're easy to reach